Eight venture investors commit another $20m to Nereus a decade after its first round to take the total raised so far to nearly $150m.

Nereus Pharmaceuticals, a US-based lung cancer drug company backed by two strategic investors, has raised $20m from eight venture firms a decade after its first round.

Three of the original venture capital investors, Alta Partners, Forward Ventures and Gimv, from the first $8.6m raised in April 2000 have returned in Nereus’ series E round.

HBM BioVentures, a venture capital firm set up by Henri Miller, the former chief financial officer of Roche, led the round alongside two corporate venturing divisions.…